ISSN Print 2713-2757
ISSN Online 2713-2765
SCIENTIFIC AND PRACTICAL REVIEWED JOURNAL OF FMBA OF RUSSIA
Copyright: © 2020 by the authors. Licensee: Pirogov University.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).
ORIGINAL RESEARCH
Using experimental ex vivo models to develop COVID-19 pathogenetic therapy and complications prevention agents
About authors
Research Institute of Hygiene, Occupational Pathology and Human Ecology Leningrad Region, Russia
Correspondence should be addressed: Denis S. Laptev
st. Kapitolovo, gor. pos. Kuzmolovsky, 93, Vsevolozhsky rajon, 188663; ur.liam@nedpal
About paper
Author contribution: Laptev DS — experimental part, information collection, data processing; Petunov SG — data processing and interpretation, general guidance; Nechaykina OV — experimental part, information collection; Bobkov DV — data processing; Radilov AS — data processing and interpretation.
Compliance with ethical standards: all work with animals was carried out in conformity to the provisions of the European Convention for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes.
Received: 2020-09-15
Accepted: 2020-12-25
Published online: 2020-12-12
|
Fig. 1. Isolated lung system. A. General view of the installation. B. Heart-lungs complex
Fig. 2. Installation of an isolated heart according to Langendorff. A. General view. B. Cannulated heart
Fig. 3. Lung weight growth rate, treatment and control groups
Fig. 4. Isolated lung perfusion pressure dynamics. The ratio of initial and final perfusion pressure is given in relative units
Fig. 5. Isolated lung intratracheal pressure dynamics
Fig. 6. End diastolic pressure dynamics, isolated heart during reperfusion after 30 minutes of total normothermic (37 °C) ischemia. APC administered. * — the
differences are statistically significant in comparison with the intact organ; # — the differences are statistically significant in comparison with the "reperfusion (control)"
group (р ˂ 0.05)
Table 1. Heart-lungs complex weight (M ± SD), n = 7
Note: * — statistically significant differences with the control series of experiments.
Table 2. Indicators of myocardial contractility with APC administered. The data provided are relative to the background, in % (M ± SE); for the EDP the data is
absolute, n = 7
Note: * — the differences are statistically significant in comparison with the intact organ; # — the differences are statistically significant in comparison with the "reperfusion (control)" group (р ˂ 0.05)
